文献速递心脑血管急症重症综合管理与镇静镇痛

心源性休克中相对性肾上腺皮质功能不全的预后价值:一项长期随访的前瞻性队列研究

Prognostic Value of Relative Adrenal Insufficiency During Cardiogenic Shock: A Prospective Cohort Study With Long-Term Follow-Up.
PubMed 文献 · Shock · 2017-01-01
一句话结论心源性休克患者中,促肾上腺皮质激素刺激试验无反应(T0>798 nmol/L且Δmax≤473 nmol/L)是死亡的独立预测因素,总生存率仅15%。

这项在法国一家大学医院ICU和心内科开展的前瞻性观察研究纳入92例未接受过糖皮质激素治疗的心源性休克患者,行短效促肾上腺皮质激素刺激试验(替可克肽0.25 mg静脉注射),检测T0及注射后30、60分钟血总皮质醇。根据T0和Δmax分为3组,总生存率分别为76%、43%、15%(log rank P=0.003)。多因素分析显示肾上腺无反应(3组)是死亡的独立预测因素(P=0.04),此外左心室射血分数、简化急性生理评分II和心脏骤停也是独立预测因素。作者认为短效促肾上腺皮质激素试验对心源性休克有良好预后价值,可识别死亡高风险患者。

要点

  • 92例心源性休克患者中,住院死亡42例(46%,95%CI 36%-56%),中位随访616天后又死亡7例,总死亡率53%(95%CI 43%-63%)。
  • 根据促肾上腺皮质激素试验分3组:1组(T0≤798 nmol/L且Δmax>473 nmol/L)总生存率76%,2组43%,3组(T0>798 nmol/L且Δmax≤473 nmol/L)15%(log rank P=0.003)。
  • 多因素分析中,肾上腺无反应(3组)是死亡的独立预测因素(P=0.04),左心室射血分数、简化急性生理评分II和心脏骤停也是独立预测因素。
  • 短效促肾上腺皮质激素试验使用替可克肽0.25 mg静脉注射,于注射前(T0)及注射后30、60分钟测血总皮质醇。

适用人群与场景

  • 法国一家大学医院ICU和心内科收治的符合心源性休克标准、且既往未接受糖皮质激素治疗的患者。

诊断标准与关键阈值

  • 相对性肾上腺皮质功能不全分组基于短效促肾上腺皮质激素刺激试验(替可克肽0.25 mg静脉注射)的T0血总皮质醇和Δmax(刺激后最大值与T0之差):1组T0≤798 nmol/L且Δmax>473 nmol/L;2组T0>798 nmol/L且Δmax>473 nmol/L,或T0≤798 nmol/L且Δmax≤473 nmol/L;3组T0>798 nmol/L且Δmax≤473 nmol/L。

处置流程与药物剂量

  • 对符合心源性休克标准且未接受过糖皮质激素治疗的患者,在行短效促肾上腺皮质激素刺激试验前立即采血测总皮质醇(T0),静脉注射替可克肽0.25 mg,并于注射后30分钟和60分钟采血测总皮质醇,计算Δmax。

研究设计与关键结果

  • 前瞻性观察研究,纳入92例心源性休克患者,住院死亡42例(46%,95%CI 36%-56%),中位随访616天[57-2498]期间又死亡7例,总死亡率53%(95%CI 43%-63%)。
  • 1组、2组、3组总生存率分别为76%、43%、15%(log rank P=0.003)。
  • 多因素分析中,肾上腺无反应(3组)是死亡的独立预测因素(P=0.04),左心室射血分数、简化急性生理评分II和心脏骤停也是独立预测因素。

证据类型、等级与局限

  • 证据类型:前瞻性观察性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为短效促肾上腺皮质激素试验对心源性休克有良好预后价值,可识别死亡风险更高的患者。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Relative adrenal insufficiency (RAI) is common in intensive care unit patients, particularly during septic shock (SS). Cardiogenic shock (CS) may share some pathophysiological features with SS. The aim of this study was to evaluate the prevalence and long-term prognosis of RAI during CS.

PATIENTS AND METHODS: Prospective observational study conducted in the intensive care and cardiology units in one university hospital in France. Patients meeting the criteria for CS without prior corticosteroid therapy were included. Total blood cortisol levels were assessed immediately before (T0) a short corticotropin stimulation test (0.25 mg i.v. of tetracosactrin) and 30 and 60 min afterward. Δmax was defined as the difference between the maximal value after the test and T0.

RESULTS: Of the 92 patients enrolled, 42 (46%) (95% confidence interval [CI] [36%-56%]) died in hospital and 7 more died during a median follow-up of 616 [57-2,498] days, for an overall mortality rate of 53% (95% CI [43%-63%]). Three groups were identified based on the corticotropin test: group 1 (T0 ≤798 nmol/L and Δmax >473 nmol/L), group 2 ([T0 >798 nmol/L and Δmax >473 nmol/L] or [T0 ≤798 nmol/L and Δmax ≤473 nmol/L]), and group 3 (T0 >798 nmol/L and Δmax ≤473 nmol/L) with an overall survival of 76%, 43%, and 15%, respectively (log rank P = 0.003). In the multivariable analysis, adrenal nonresponse (group 3) was an independent predictor of mortality (P = 0.04), along with left ventricular ejection fraction, Simplified Acute Physiology Score II, and cardiac arrest.

CONCLUSIONS: These data suggest that a short corticotropin test has a good prognostic value in CS and allows identifying patients at higher risk of death.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Bagate F, Lellouche N, Lim P, et al. Prognostic Value of Relative Adrenal Insufficiency During Cardiogenic Shock: A Prospective Cohort Study With Long-Term Follow-Up. Shock. 2017. PMID: 27984534

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。